NY-CLINIQUE
2.2.2024 15:01:27 CET | Business Wire | Press release
Clinique and Icahn School of Medicine at Mount Sinai today announced a philanthropic partnership to establish the Mount Sinai-Clinique Healthy Skin Dermatology Center. The Center will develop forward-thinking research in dermatology, exploring the biological underpinnings of how skin ages, skin allergies and inflammatory or eczematous skin conditions, including eczema (or atopic dermatitis) and contact dermatitis. Rooted in a shared mission to conduct dermatological research that improves patients’ lives, the partnership will focus on applicable scientific discovery and leading-edge innovation to modernize allergy science in order to identify innovative solutions for these skin conditions.
Research conducted under the Mount Sinai-Clinique Healthy Skin Dermatology Center aims to uncover scientific findings to accelerate the creation of new topical and systemic treatments that help alleviate allergic skin conditions. The priority is to bridge basic science with practical application in the clinic to improve people’s lives through healthy skin. By investigating healthy skin, along with the skin of those with atopic dermatitis and other allergic skin disorders, the researchers may learn how to significantly slow the visible signs of aging in all people as well as in patients with eczema, who show signs of premature or accelerated aging. Insights from this research aim to spur advances in the field of dermatology and skin health. Additionally, they will inform and inspire Clinique in future product innovation to offer further solutions for people with allergic or sensitive skin.
“As a brand that has offered dermatologist guided solutions and allergy tested solutions since its inception, Clinique is proud to partner with the renowned institution of Icahn Mount Sinai and its team of physician-scientists, led by a world-renowned expert in allergic and inflammatory skin diseases, Dr. Emma Guttman. We are inspired by the team’s dedication to the research and future discoveries of allergic skin and its life impact, including aging. We are energized by our mutual commitment and steadfast belief that great skin can be created and maintained for all. I am confident that this first-of-its-kind partnership will enable groundbreaking research by leading physician-scientists dedicated to advancing allergy science,” Michelle Freyre, President, Global Brands, Clinique.
Dr. Emma Guttman, MD, PhD, Waldman Professor and System Chair, Department of Dermatology at the Icahn School of Medicine, a trailblazer in dermatologic science, has dedicated her career to bridging science with practice intended to improve patients’ lives. Her work has led to novel therapeutic targets for patients suffering from inflammatory skin conditions. Drawing inspiration from her personal and family history of eczema and other allergic conditions, Dr. Guttman has made it her mission to alleviate sensitive skin.
“Years of chronic inflamed skin plays a role in premature aging. Extensive research has helped us understand the molecular map of skin conditions associated with allergy such as eczema and contact dermatitis, and we’re now at a pivotal point in addressing these conditions and more. With Clinique’s support, we will continue to actively explore targeted approaches to reversing eczematous and allergic skin conditions with the goal of creating and sustaining healthy skin. In turn, we want to use this understanding to address and prevent the process of age-related inflammation or ‘inflammaging’ in the first place,” says Dr. Guttman, who also directs the Center of Excellence in Eczema at Mount Sinai and the Laboratory of Inflammatory Skin Diseases at Icahn Mount Sinai.
The laboratory of Inflammatory Skin Diseases at Icahn Mount Sinai has a major focus on atopic dermatitis, contact dermatitis, alopecia areata, and other inflammatory skin diseases. It has made paradigm-shifting discoveries on the immunologic basis of atopic dermatitis, opening the door to new therapeutics. Dr. Guttman’s lab developed the only comprehensive molecular maps of atopic dermatitis, defining skin differentiation and immune-circuits characterizing this disease across phenotypes and ages. This work on atopic dermatitis/eczema has contributed directly to many of the recently developed treatments for this disease, earning Dr. Guttman and her lab a unique place as being a top leader in dermatology and immunology worldwide.
Clinique has a long-standing history of partnering with dermatologists, including its Founding Dermatologist, Norman Orentreich, MD, and incorporating patients’ insights in its innovation since 1968. His children, Catherine Orentreich, MD, and David Orentreich, MD, the brand’s Guiding Dermatologists, continue their father’s legacy for Clinique. Dr. David Orentreich is Assistant Clinical Professor of Dermatology at Icahn Mount Sinai, and he and Dr. Catherine Orentreich are members of the Mount Sinai Dermatology Advisory Board.
In this meaningful mission, Clinique has made a philanthropic commitment of $5 million over seven years for the advancement and evolution of allergy science through the partnership and founding of the Mount Sinai-Clinique Healthy Skin Dermatology Center. The funds will be used to recruit the best and brightest physicians and scientists, and provide resources for the most advanced equipment, clinical and laboratory space, and key support staff. The studies conducted by the Mount Sinai-Clinique Healthy Skin Dermatology Center will include all ages, genders, races and ethnicities, and will also investigate the effects of factors such as diet, exercise, and stress on the skin of healthy people. Mount Sinai predicts that with Clinique’s support, critical breakthroughs will be fast-tracked, from the earliest stages of the multiyear partnership.
About Mount Sinai Health System:
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, more than 400 outpatient practices, more than 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it. Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,400 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2023-2024.
About Clinique:
In 1968, a beauty editor asked a leading New York City dermatologist, “Can great skin be created?” The answer: yes. And with that yes, Clinique was born. Today Clinique is the #1 Dermatologist Brand in Skincare in the US* and #1 Dermatologist Brand in Makeup in the US**, offering its dermatologist guided, allergy tested solutions for remarkable skin results. The brand is sold in 107 markets worldwide. Clinique’s clinical solutions are informed by years of research, working with dermatologists, scientists, and ophthalmologists. All Clinique formulas are designed to deliver powerful efficacy with rigorous safety —clinically proven, allergy tested, and 100% fragrance free.
*Source: Circana, U.S. Prestige Beauty Total Measured Market, Skincare Unit Sales, Derm Brand Attribute, 12 Months Ending December 2023
**Source: Circana, U.S. Prestige Beauty Total Measured Market, Makeup Unit Sales, Derm Brand Attribute, 12 Months Ending December 2023
Derm Brand is defined as a brand that was founded or developed by a dermatologist and/or is dermatologist recommended.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240202954316/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF to Webcast Fireside Chat at Barclays Global Consumer Conference on Sept. 1018.8.2026 22:15:00 CEST | Press release
IFF (NYSE: IFF) today announced that Chief Executive Officer Erik Fyrwald will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, Sept. 10, 2026 at 945 a.m. ET. Investors may access the live webcast on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, and health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire.com/news/home/20260818490253/en/
Lehman Brothers Treasury Announces the Successful Sale of its Remaining Intercompany Claim against Lehman Brothers Holdings Inc.18.8.2026 21:15:00 CEST | Press release
In connection with its previously announced final wind-down, Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”), through its U.S. counsel Herbert Smith Freehills Kramer (US) LLP, announced that its placement agent, Seaport Loan Products LLC, successfully closed the sale of LBT’s remaining $19.6 billion Class 4A intercompany claim against Lehman Brothers Holdings Inc. The net proceeds of the sale, together with certain available cash (but after deducting various sale-related and other administrative costs and expenses), will be used to fund a final distribution to the holders of LBT’s existing notes, after which such existing notes will be canceled and LBT shall be fully wound down. As a result, LBT will cease to exist. LBT expects the final distribution to occur in the course of October 2026 and the wind down to have been completed before the end of 2026. View source version on businesswire.com: https://www.businesswire.com/news/home/20260818004215/en/
GenBio AI Builds First World Model of the Human Cell18.8.2026 15:00:00 CEST | Press release
First-of-its-kind system simulates human cell behavior across the full biological hierarchy, from DNA and RNA through protein to the whole-cell level GenBio AI ('GenBio') is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford, Carnegie Mellon University, Mohamed Bin Zayed University of Artificial Intelligence, Harvard, Weizmann Institute, and other research institutions. Today, the company introduced AIDO Cell, its virtual cell world model — the first system capable of simulating a human cell, both in its natural state and in response to drugs and other interventions, across its full biological hierarchy, from DNA and RNA through protein to the whole-cell level. A Key First in Biological and Medical Sciences: Full-hierarchy virtual cell simulation has been widely identified as a key milestone in computational biology. Compared to the previous efforts by
Xsolla Partner Network Expands Verified Creator Partnerships and Unifies Campaign Management Ahead of gamescom 202618.8.2026 15:00:00 CEST | Press release
Developers Gain Vetted Creator Partnerships And A Single Campaign Workflow, Managed From The Publisher Account They Already Use Xsolla, a global video game commerce company, today announced an expansion of the Xsolla Partner Network ahead of gamescom 2026 in Cologne, giving game developers a simpler, more reliable way to grow their games through creators. The creator platform now lives within Xsolla Publisher Account, where developers already run their business, with verified creator onboarding and a redesigned and unified campaign workflow. Flat-fee campaigns, a new guaranteed payment option alongside revenue share, and data-driven creator recommendations are coming soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818140062/en/ Graphic: Xsolla Xsolla Partner Network gives developers one place to launch, manage, track, and report on creator campaigns while Xsolla handles payments, payouts, taxes, and compliance.Verifi
KOCCA to Showcase 13 Korean Game Companies at ‘Gamescom 2026’ with PC, Mobile, and VR Lineups18.8.2026 14:48:00 CEST | Press release
- Featuring a diverse lineup of roguelike deckbuilders, AI-powered rhythm education, and cooperative horror games - Ranging from new titles based on the popular animated IP ‘LARVA’ to real-time K-POP dance coaching content - Hands-on experience available August 26–28 at the Korea Joint Pavilion B2B Hall, Koelnmesse, Booth Hall 3.2 C-050g–D051g The Korea Creative Content Agency (KOCCA) announced that 13 Korean game companies will gather under one roof at Gamescom 2026, Europe’s largest game show, held in Cologne, Germany, from August 26 to 28 (B2B, 09:00~20:00). Located in Booth Hall 3.2 C-050g–D051g, the Korea Joint Pavilion offers visitors hands-on experiences with an expansive lineup of titles, ranging from PC and mobile games to VR-powered titles across diverse genres. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818271881/en/ KOCCA will bring 13 Korean game companies to Gamescom 2026 in Cologne, Germany (Image: KOCC
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
